We are delighted to announce that Eagle IP has been recognized once more by IAM Patent 1000 - The World's Leading Patent Professionals - as a top ranked, “Highly Recommended Firm in Patent Prosecution”.

The IAM Patent 1000 is a respected annual directory dedicated to identifying leading patent firms and individual practitioners globally. Published by Intellectual Asset Management (IAM), the guide covers key jurisdictions and evaluates capabilities across the core areas of patent law. Inclusion in the directory is determined by a rigorous, independent research process that includes 900+ extensive interviews with in-house counsel, patent attorneys, and industry experts.

According to IAM, Eagle IP has carved out “a distinctive reputation for far-reaching and highly sophisticated patent protection” and “a prime pick for life sciences companies, research institutions and technology-driven enterprises navigating complex international patent strategies.”

IAM has further highlighted five individuals from our firm: Our President and Managing Director, Ms. Jennifer Che, Principal Ms. Yolanda Wang, Principal Ms. Pauli Wong, Dr. Jacqueline C Lui, Dr. Ho Chung Lui.

We are incredibly honoured to be included in this highest category among a select group of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US, Chinese, and Hong Kong patent laws, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

Our Past Events

Recommended Insights

Everything you need to know about Patent Term Adjustment (PTA) in China

7 May 2024
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]

How the Chinese Patent Office Rejected a Plate-Making Method Based on Food Safety Law

19 October 2022
Previously we published an article about CNIPA rejecting a patent application claiming a food that could also be used to treat or prevent diseases based on the food’s alleged non-compliance with Food Safety Law. China’s Food Safety Law includes a provision which states any use of a composition as a food must be strictly separated […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

4 February 2025
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

28 April 2021
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]
Top crossarrow-right